The FDA has granted full approval for Laverdia, the first oral at-home treatment for canine lymphoma, developed by Anivive Lifesciences and distributed by Dechra. As an XPO1 inhibitor, it represents a new class of veterinary cancer treatment, and it's designed to be administered by pet owners at home rather than in a clinic.
The significance goes beyond this one drug. It's a signal that the future of some veterinary treatment is outpatient and at-home by design, not a workaround for when a clinic visit isn't feasible.
Care Is Moving Outside the Clinic on Multiple Fronts
Laverdia isn't an isolated development. Access to veterinary care has been under real pressure: a recent industry survey found nearly half of pet owners have delayed or skipped care due to cost, and states including Rhode Island have begun loosening telehealth rules that previously required an in-person visit before virtual care could be used.
The shift is broader than any single law or drug. Chewy Health published a free 2026 CE calendar covering both medical topics and non-medical skills, explicitly designed for distributed, digitally enabled veterinary teams. The profession is slowly but steadily building infrastructure for care that doesn't require every touchpoint to happen in a clinic.
What This Means for Practices
At-home and outpatient models are quickly becoming standard infrastructure across the industry. A few developments practices should track:
- New at-home treatment options like Laverdia change what compliance looks like for owners managing a chronic or serious diagnosis. Practices should be ready to support at-home dosing with clear monitoring guidance.
- Telehealth and CE investment are both signals of where the industry is headed. Practices that build capability now won't be scrambling to catch up later.
- Access barriers, cost, distance, and clinic-based stress, are being addressed on multiple fronts at once. No single fix solves it, but the combination is real progress.